1-2 of 2
gemtuzumab
Close
Sort by
Journal Articles

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)

Clinical Trials & Observations
Jeffrey E. Lancet, Anna B. Moseley, Steven E. Coutre, Daniel J. DeAngelo, Megan Othus, Martin S. Tallman, Mark R. Litzow, Rami S. Komrokji, Harry P. Erba, Frederick R. Appelbaum
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1683–1689.
https://doi.org/10.1182/bloodadvances.2019001278
Published: 2020
Journal Articles

The role of targeted therapy in the management of patients with AML

Clinical Trials & Observations
Alexander E. Perl
Journal: Blood Advances
Blood Adv (2017) 1 (24): 2281–2294.
https://doi.org/10.1182/bloodadvances.2017009829
Published: 2017